✦ LIBER ✦

Intra-Arterial Therapies for Hepatocellular Carcinoma: Where Do We Stand?

✍ Scribed by Eleni Liapi; Jean-Francois H. Geschwind

Book ID: 111773501
Publisher: Springer
Year: 2010
Tongue: English
Weight: 281 KB
Volume: 17
Category: Article
ISSN: 1068-9265
DOI: 10.1245/s10434-010-0977-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Markers for microvascular invasion in he

Markers for microvascular invasion in hepatocellular carcinoma: Where do we stand?

✍ Annette S. H. Gouw; Charles Balabaud; Hironori Kusano; Satoru Todo; Takafumi Ich 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 139 KB

It is well known that hepatocellular carcinoma (HCC) commonly involves the local branches of portal and/or hepatic veins and causes a tumor thrombus even at a relatively early stage. Vascular invasion is classified as macrovascular invasion, which is grossly recognizable (mostly in large to medium v

Gene Therapy for Peripheral Arterial Dis

Gene Therapy for Peripheral Arterial Disease: Where Do We Stand Now?

✍ Golden, Michael A. 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 533 KB

Role of Transcatheter Intra-arterial The

Role of Transcatheter Intra-arterial Therapies for Hepatocellular Carcinoma

✍ Paul, Shashi B.; Sharma, Hanish 📂 Article 📅 2014 🏛 Elsevier 🌐 English ⚖ 739 KB

Gene therapy for arthritis – where do we

Gene therapy for arthritis – where do we stand?

✍ Yuti Chernajovsky 📂 Article 📅 2005 🏛 BioMed Central 🌐 English ⚖ 44 KB

Endovascular Therapy of Renal Artery Ste

Endovascular Therapy of Renal Artery Stenosis: Where Do We Stand Today?

✍ Michael Uder; Ulrich Humke 📂 Article 📅 2005 🏛 Springer 🌐 English ⚖ 167 KB

Gene Therapy for Heart Failure: Where Do

Gene Therapy for Heart Failure: Where Do We Stand?

✍ Naim, Charbel; Yerevanian, Armen; Hajjar, Roger J. 📂 Article 📅 2013 🏛 Springer 🌐 English ⚖ 207 KB